ArticleMolecular cancer research : MCR2021
The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics.
Open access · greenAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Integrated stress response activation in combination PG3 and cisplatin-treatedbioRxiv : the preprint server for biology · 2026Article
- Article
- Mitochondrial integrated stress response activation creates a therapeutic vulnerability to MCL-1 inhibition in acute myeloid leukemia.Cell death & disease · 2026Article
- Structural insights into allosteric inhibition of HRI kinase by heme binding via HDX-MS.The Biochemical journal · 2025Article
- HRI protein kinase in cytoplasmic heme sensing and mitochondrial stress response: Relevance to hematological and mitochondrial diseases.The Journal of biological chemistry · 2025Review
- Rapid and robust validation of pooled CRISPR knockout screens using CelFi.Scientific reports · 2025Article
- Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models.Blood advances · 2025Article
- Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer.Cancers · 2024Article
- Pharmacologic activation of a compensatory integrated stress response kinase promotes mitochondrial remodeling in PERK-deficient cells.Cell chemical biology · 2023Article
- Pharmacologic Activation of a Compensatory Integrated Stress Response Kinase Promotes Mitochondrial Remodeling in PERK-deficient Cells.bioRxiv : the preprint server for biology · 2023Article
- Targeting regulated cell death pathways in acute myeloid leukemia.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Targeting the integrated stress response in hematologic malignancies.Experimental hematology & oncology · 2022Review
- Stressed to death: Mitochondrial stress responses connect respiration and apoptosis in cancer.Molecular cell · 2022Review
- Heme-regulated inhibitor: an overlooked eIF2α kinase in cancer investigations.Medical oncology (Northwood, London, England) · 2022Review
- Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS).International journal of molecular sciences · 2021Article
- Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.Blood advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Kaitlyn H Smith *Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Amit Budhraja *Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
John LynchDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Kathryn RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7626-4043
John C PanettaDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jon P ConnellyDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-5564-1775
Meghan E TurnisDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Shondra M Pruett-MillerDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-3793-585X
John D SchuetzDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-1871-1850
Joseph T OpfermanDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee. Joseph.Opferman@stjude.org.
St. Jude Children's Research Hospital · US
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MTranslating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4MTransporters and MedulloblastomaR01CA194057 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SCHUETZ, JOHN D · 2015 to 2025
$4.0MTransporters and hematopoietic toxicityR01CA194206 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SCHUETZ, JOHN D · 2016 to 2020
$2.4MRegulation of Cell Death and Mitochondrial Physiology by Anti-Apoptotic MCL-1R01HL102175 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI OPFERMAN, JOSEPH T. · 2010 to 2014
$2.1MPathway Specific Combinational Therapy in Poor Prognosis B-Lineage Acute Lymphoblastic LeukemiaR01CA201069 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI OPFERMAN, JOSEPH T. · 2016 to 2020
$2.0MRegulation of Cardiac Death and Energy Metabolism by MCL-1R01HL123543 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI OPFERMAN, JOSEPH T. · 2015 to 2018
$1.8MNCI NIH HHS P30 CA021765NCI NIH HHS R01 CA194057NCI NIH HHS R01 CA194206NCI NIH HHS R01 CA201069NCI NIH HHS R35 CA197695NHLBI NIH HHS R01 HL102175NHLBI NIH HHS R01 HL123543
Abstract
Antiapoptotic
Indexed as
AnimalsBiomimeticsCell Line, TumorEnzyme ActivationFemaleHumansLeukemia, Myeloid, AcuteMiceMice, KnockoutPeptide FragmentsPrognosisProto-Oncogene ProteinsBax protein (53-86)Peptide FragmentsProto-Oncogene Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.